Population Pharmacokinetics study of Imatinib
Phase 4
- Conditions
- Chronic myeloid leukaemia (CML).Chronic myeloid leukaemia [CML], BCR/ABL-positive
- Registration Number
- IRCT2014050612206N1
- Lead Sponsor
- Kerman University of Medical Sciences
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete
- Sex
- All
- Target Recruitment
- 220
Inclusion Criteria
patients with CML in chronic phase who take Imatinib from diagnosis and have no other disease.
Exclusion Criteria
taking Interfron or Hydroxyurea in past or during the study; taking drugs that induce or inhibit liver microsomal enzymes and patients in accelerated or blastic phases.
Study & Design
- Study Type
- interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Trough plasma concentration. Timepoint: Before taking the dose. Method of measurement: HPLC.
- Secondary Outcome Measures
Name Time Method Hematological response. Timepoint: every 3 months. Method of measurement: CBC Check.